For Q1 FY2026 ended March 31, 2026, Cytek Biosciences reported revenue of $44.1 million, up 6.5% year-over-year. Net loss widened to $18.9 million from $11.4 million in the prior year quarter, while operating loss increased 23.3% to $18.5 million. The company held $65.7 million in cash and $327.6 million in equity, with no long-term debt.
•Revenue grew 6.5% YoY to $44.1 million.
•Net loss increased 65.5% to $18.9 million.
•Operating loss rose 23.3% to $18.5 million.
•Cash and cash equivalents stood at $65.7 million with no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Cytek Biosciences, Inc., a cell analysis solutions company provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis.
Its portfolio also includes Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches, enhanced small particle detection, Cytek amnis imagestream imaging flow cytometers, Cytek guava muse cell analyzers, Cytek muse micro cell analyzers, Cytek guava easyCyte flow cytometers, and Cytek orion reagent cocktail preparation systems
Reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. Additionally, it offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems.
Its portfolio also includes SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems, and customer support tools
Conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations.
It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions Through distributors or sales agents in Europe, Latin America, and the Middle East countries. Founded in 1992 and headquartered in Fremont, California, Cytek Biosciences was formerly known as Cytoville, Inc. before rebranding in August 2015.
Cytek Biosciences, Inc. is a cell analysis solutions company that provides tools for biomedical research and clinical applications. Its main products include the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, which deliver advanced cell analysis capabilities. The company also offers the Cytek Aurora CS System for downstream genomic and proteomic studies, enhanced small particle detection, and imaging flow cytometers under the Amnis brand, such as the Amnis ImageStream. Additionally, it provides Guava and Muse cell analyzers, the Guava easyCyte flow cytometers, and the Orion reagent cocktail preparation systems. Cytek also sells reagents and kits, including cFluor fluorochrome conjugated antibodies, and software like SpectroFlo for workflow and data analysis. Its portfolio includes conventional flow and image-based flow cytometry instruments and related services under the Amnis and Guava brands.
Where is Cytek Biosciences listed and in which currency?
Cytek Biosciences, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol CTKB. Its shares are traded in United States Dollars (USD), as the company is based in the United States. The exchange is a major US stock exchange, providing liquidity and visibility for the company's stock.
What sector and industry does Cytek Biosciences operate in?
Cytek Biosciences operates in the Healthcare sector, specifically within the Medical Devices industry. This classification reflects its focus on developing and manufacturing cell analysis instruments, reagents, and software used in biomedical research and clinical diagnostics. As a medical devices company, it provides tools that help researchers and clinicians analyze cells for various applications, including immunology, oncology, and drug discovery.
Who are Cytek Biosciences' main customers and how does it distribute its products?
Cytek Biosciences serves pharmaceutical and biopharmaceutical companies, academic research centers, and contract research organizations (CROs). These customers use its cell analysis tools for research and development, clinical trials, and diagnostic applications. The company distributes its products primarily through a direct sales force, allowing it to maintain close relationships with customers and provide tailored support. This direct distribution model helps Cytek effectively market its advanced systems, reagents, and software to a specialized scientific audience.
What are some notable products in Cytek Biosciences' portfolio?
Cytek Biosciences offers a range of notable products. Its flagship systems include the Cytek Aurora, Northern Lights, and Cytek Aurora Evo, which provide high-parameter cell analysis. The Cytek Aurora CS System enables additional downstream genomic and proteomic studies. The company also provides imaging flow cytometers under the Amnis brand, such as the Amnis ImageStream, and cell analyzers under the Guava and Muse brands, including the Guava easyCyte and Muse Micro Cell Analyzers. Additionally, it offers the Orion reagent cocktail preparation system, cFluor reagents (fluorochrome conjugated antibodies), and the SpectroFlo software for instrument control and data analysis. Automated accessories like the automated micro-sampling system and sample loader are also part of the portfolio.